To determine the outcome of patients with chemosensitive relapsed or primary refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) whose disease progresses after autologous stem cell transplantation (ASCT), we reviewed the records of 82 patients with HD and 139 patients with NHL transplanted between 1993 and 2000. Disease progression occurred in 25 patients with HD and 66 patients with NHL, with median times to progression (TTP) of 3.8 and 5.1 months, respectively. Median survival times following ASCT failure were 26 and 7.7 months for patients with HD and NHL, respectively. The second-line international prognostic index (sIPI) and the TTP (before or after 3 months from ASCT) independently were predictive of survival for NHL patients. In addition, treatment with rituximab for patients with B cell NHL was associated with improved survival (median 28.6 vs 4.1 months, P ¼ 0.003), independent of the sIPI and TTP. Prognostic factors for patients with HD were not identified. Only two patients, one of whom was among six patients who received second autologous transplants, remain disease-free. The uniformly poor outcome associated with disease progression after ASCT should prompt efforts to assess the feasibility and utility of detecting and treating post transplant residual disease during a minimal disease state, before overt progression.
ease; Hodgkin's disease; non-Hodgkin's lymphoma High-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (ASCT) is a standard therapy for patients with chemosensitive relapsed or primary refractory aggressive non-Hodgkin's lymphoma (NHL) [1] [2] [3] and Hodgkin's disease (HD). 4, 5 Unfortunately, despite having chemosensitive disease, 50-65% of patients with aggressive NHL and 35-55% of patients with HD will have progressive disease after ASCT. It is commonly accepted that the outcome of patients with progressive disease after ASCT is uniformly poor, but there have been few formal assessments. Vose et al 6 reported that the median survival times of patients with HD or aggressive NHL in whom ASCT failed were 10.5 months and 3 months, respectively. However, the majority of patients in that series did not have chemosensitive disease, a criterion now considered essential for patients to undergo ASCT. Similarly, in a series of 37 patients with HD in whom ASCT failed, 27% of whom had chemoresistant disease, the median survival was 8.5-12 months. 7 We postulated that survival following the failure of ASCT in patients with chemosensitive disease would be longer than believed. In addition, we wanted to determine what proportion of patients had long-term remissions after ASCT failure and if prognostic factors for survival could be identified. To address these issues, we reviewed the outcome of patients who underwent ASCT for relapsed or primary refractory disease that was sensitive to second-line chemotherapy but whose disease subsequently progressed.
Patients and methods

Patients
We identified 221 patients with relapsed or primary refractory HD (82 patients) or aggressive NHL (139 patients) who underwent ASCT at Memorial SloanKettering Cancer Center (MSKCC) between April 1993 and March 2000. All patients received second-line therapy and/or ASCT on Institutional Review Board approved clinical trials after providing informed consent. The records of those patients who had progressive disease after ASCT were reviewed. All patients attained at least a partial response (PR) to ICE chemotherapy (ifosfamide, carboplatin, and etoposide) before proceeding to ASCT; details of the ICE regimen for patients with relapsed or primary refractory HD 8 or aggressive NHL 9 have been published previously. Diagnoses for all patients were confirmed by MSKCC hematopathologists.
HDT and ASCT
Adequate pulmonary function (diffusion capacity greater than 50% of predicted), cardiac function (ejection fraction greater than 50%), and liver function (serum bilirubin less than 2 mg/dl) were required of all patients prior to undergoing ASCT. The choice of conditioning regimen depended on the patient's age, the extent of prior therapy, and the clinical trials active at the time of transplantation. Total lymphoid irradiation (TLI) or total body irradiation (TBI) for HD or aggressive NHL, respectively, was a component of the conditioning regimen only if the patient had not received prior radiotherapy. Prior to ASCT, involved-field radiotherapy was administered to involved sites that measured greater than 5 cm prior to ICE and/or to sites of residual disease after ICE, provided there were no more than two such sites. All patients received unmanipulated stem cell grafts.
Post transplant evaluation
Response to ASCT was planned to be assessed by computed tomography (CT) approximately 90-100 days after stem cell infusion. Patients with evidence of disease progression by physical exam and/or CT scans at any time after ASCT were analyzed for this report. Nine patients (HD two patients, NHL seven patients) who died of transplant-related complications were excluded from this analysis. Patients with evidence of progressive disease at or before the 90-day restaging studies were classified as having disease that was refractory to ASCT ('ASCT refractory'); patients who were progression-free at the time of the 90-day restaging studies but who subsequently had evidence of progressive disease were considered to have disease that relapsed after ASCT ('ASCT relapse').
Treatment after disease progression
The choice of therapy after disease progression was at the discretion of the primary physician. For purposes of this report, each chemotherapy regimen, each course of monoclonal antibody therapy, each course of radiotherapy, and a second transplant, whether autologous or allogeneic, was considered a distinct treatment course; treatment with steroids alone was not considered a treatment regimen.
Statistics
The time to progression (TTP) was defined as the time from stem cell infusion to documentation of disease progression. Survival times were calculated both from the time of ASCT and the time of ASCT failure to death or last follow-up using the method of Kaplan and Meier. 10 Univariate analyses were performed using the log-rank test, 11 and factors that were potentially predictive of overall survival (OS) (Po0.05) were entered into a multivariable analysis using the Cox proportional hazards model. 12 Categorical variables were compared using the Fisher exact test. 13 Univariate analyses and comparisons of categorical variables were performed using SPSS 10.0 (SPSS Inc., Chicago, IL, USA). Cox regression analysis was performed using S-PLUS 2000 (Mathsoft Inc., Seattle, WA, USA).
Results
Hodgkin's disease
At a median post transplant follow-up time of 32 months for surviving patients, progressive disease was noted in 25 of the 82 patients (30%); their characteristics are listed in Table 1 . Adequate data with regard to determining if patients had at least three of the seven risk factors of the HD prognostic score (HDPS), a prognostic index developed for patients undergoing first-line therapy 14 and that is also applicable to patients undergoing ASCT, 15 were available for 21 of the 25 patients. At the time of progressive disease, the majority of patients had fewer than three risk factors of the HDPS.
The median TTP was 3.8 months ( Figure 1a ). The median survival times from ASCT and ASCT failure are 33 months and 26 months, respectively ( Figure 1b ). Owing to the relatively narrow age range of the patients studied and the relatively small number of patients, age was not assessed for its prognostic value for survival. With the possible exception of the HDPS, none of the factors considered were predictive of survival (Table 2) . Patients with an HDPS of less than 3 had a median survival of 36 months compared to 22 months for patients with an HDPS of 3 or greater (P ¼ 0.07).
Adequate data with regard to treatment after ASCT failure were available for 20 of the 25 patients (80%) ( Table 3 ). Two of the 20 patients had cytopenias (an absolute neutrophil count less than 1000/ml and/or a platelet count less than 100 000/ml) at the time of progressive disease; however, both received myelosuppressive salvage therapy. One patient with ASCT-refractory disease underwent a nonmyeloablative allogeneic transplant from an HLA-matched sibling after responding to intermittent salvage chemotherapy for 2.5 years; he had persistent disease in the setting of graft-versus-host disease and died of disease progression 13 months after the allogeneic transplant. Four patients underwent second autologous transplants after responding to further standard-dose chemotherapy, but only one remains disease free, 42 months from the second transplant; he is the only patient who remains disease free.
Aggressive non-Hodgkin's lymphoma
At a median post transplant follow-up time of 29 months for surviving patients, progressive disease was noted in 66 of the 139 patients (47%) with aggressive NHL, with a median TTP of 5.1 months ( Figure 1a) ; patient characteristics are listed in Table 1 . In all, 43 patients had good-risk disease by the second-line International Prognostic Index (sIPI), that is, the IPI determined at the initiation of second-line chemotherapy. 16 The median survival times from ASCT and ASCT failure are 14 months and 7.7
Progressive disease after ASCT for NHL and HD months (Figure 1b) , respectively. Both the TTP and the sIPI were independently prognostic for survival (Po0.001 and P ¼ 0.003, respectively) ( Tables 2 and 4 ). The median survival time from ASCT failure is 17 months for ASCTrelapsed patients compared to 3 months for ASCTrefractory patients (Figure 2) . Furthermore, patients with disease that relapsed more than 12 months from ASCT, representing 18% of patients with aggressive NHL in whom ASCT failed, have a relatively good outcome with a median survival that has not yet been reached (median follow-up 26 months; data not shown). 14 was based on seven adverse features determined at the time of ASCT failure: age of 45 years or greater, male sex, stage IV disease, a serum albumin less than 4 g/dl, a hemoglobin level less than 10.5 g/dl, a white cell count of 15 000/ml or greater, and a lymphocyte count less than 600/ml. Adequate data with regard to treatment after ASCT failure were available for 56 of the 66 patients (85%) (B cell 47 patients, T cell nine patients), and their treatment is summarized in Table 3 . Of the 56 patients, 19 had cytopenias at the time of progressive disease, and patients with ASCT-refractory disease were more likely to have cytopenias compared to patients with ASCT-relapsed disease (Po0.001). Seven of the 19 patients with cytopenias received myelosuppressive therapy as their initial salvage therapy. Five patients with ASCT-refractory disease did not receive treatment due to a poor performance status associated with rapidly progressive disease and had a median survival of 23 days (range 4-31) from the time of disease progression. Two patients underwent second autologous transplants and both had progressive disease, 8 and 10 months following the second transplants. One patient, with peripheral T cell lymphoma that relapsed 6 months after ASCT, remains alive without evidence of disease 4 years after completing treatment with oral chlorambucil, etoposide, procarbazine, and prednisone.
Among the 47 patients with a B cell phenotype, 21 died before the commercial availability of rituximab, whereas 20 of the other 26 patients were treated with at least one course of rituximab as part of their salvage therapy. The 20 patients who received rituximab lived significantly longer than the 27 patients who did not receive rituximab, with median survival times of 28.6 and 4.1 months, respectively, from the time of ASCT failure ( Figure 3 ). The sIPI (P ¼ 0.355) and the TTP (P ¼ 0.767) were not different for the patients treated with rituximab compared to the patients who were not treated with rituximab. The significant clinical effect of rituximab administration was retained in a multivariable analysis that accounted for the sIPI and the TTP, such that the hazard ratios for rituximab administration, the sIPI, and the TTP were 3.0 (95% confidence interval, 1.4-6.2), 2.9 (95% confidence interval, 1.4-6.2), and 4.0 (95% confidence interval, 1.9-8.2), respectively.
Discussion
Although chemosensitivity clearly is the most important determinant of the outcome of ASCT for relapsed or primary refractory HD [17] [18] [19] and aggressive NHL, 20 a significant proportion of patients with chemosensitive disease have progressive disease after ASCT. The outcome of these patients is difficult to assess from prior studies, 6, 7 which have included patients with chemoresistant disease, Progressive disease after ASCT for NHL and HD a group with a poor prognosis now known to derive only marginal benefit from ASCT. We describe the outcome of patients with chemosensitive disease who have progressive disease after ASCT and identify prognostic factors for their survival. Despite significant differences in the biology of HD and aggressive NHL, their failure patterns following ASCT are remarkably similar, with a median TTP of 4-5 months. However, as previously noted, 6, 8, [21] [22] [23] [24] [25] although relapse more than 2 years following ASCT is rare for patients with HD, patients with aggressive NHL are at risk for late relapses. Bolwell et al, 24 for example, noted relapses of aggressive NHL as late as 40 months from ASCT, and in our report 10% of patients relapsed more than 2 years from ASCT. Similarly, Bierman et al 25 observed a 12% recurrence rate among patients free of disease for 4 or more years after ASCT. These findings highlight the importance of continued long-term surveillance following ASCT, particularly for patients with aggressive NHL.
The long TTP among a subset of aggressive NHL suggests an indolent growth pattern and implies a better prognosis. Indeed, the median survival has not been reached for patients who relapse more than 1 year from ASCT, in contrast to a median survival of only 3 months for patients with progressive disease within 3 months from ASCT. Others have noted a similar phenomenon, 6, 25 and in the study by Bierman et al 25 67% of patients with relapses that occurred more than 4 years from ASCT were alive 4 years from relapse. In addition to the prognostic importance of the TTP, the sIPI was also predictive of survival. It is likely that both the TTP and the sIPI serve as surrogate markers for a tumor's biologic characteristics and kinetics, and studies that assess the biologic profile of lymphomas, as has been carried out using gene-expression analysis for de novo aggressive NHL, 26, 27 may help identify prognostic groups more accurately.
Contrary to previous observations by others 28 and us 9 that patients transplanted in complete remission lived longer than those transplanted in partial remission, the OS of patients in this series was not affected by their pretransplant remission status. Possible reasons for this discrepancy include the smaller number of patients in this analysis and insufficient power to detect the difference (a type II error), the exclusion of certain histologies in this analysis (16% of patients in our prior report had either mantle cell lymphoma, small lymphocytic lymphoma, or follicular lymphoma), and/or that our previous results were erroneous (a type I error). Indeed, the prognostic significance of remission status at ASCT is controversial and needs to be assessed in a larger set of patients. In contrast to aggressive NHL, we could not identify clinical features of HD that correlated with survival. Only the HDPS, applied at the time of ASCT failure, appeared to be potentially prognostic (P ¼ 0.07), although the small number of patients limited the power of this analysis. It would be of interest to assess the utility of the HDPS in a larger cohort of patients.
Cytopenias and a poor performance status characterize many patients with progressive disease after ASCT, particularly those with ASCT-refractory disease, and nonmyelosuppressive agents such as rituximab are therefore attractive agents for use in the setting of ASCT failure. It is not surprising that the majority of patients with B cell NHL received rituximab as part of their salvage therapy. However, their longer survival compared to patients with a similar sIPI and TTP profile who did not receive rituximab was unexpected. Preliminary phase II data suggest that rituximab administration as consolidation following ASCT for chemosensitive relapsed or primary refractory aggressive B cell NHL significantly reduces the relapse rate compared to historical controls. 29 In addition, in the pivotal trial of rituximab for relapsed or primary refractory low-grade lymphoma, the highest response rates were noted in patients post ASCT. 30 The apparent dominance of antibody-dependent cell-mediated cytotoxicity as rituximab's mechanism of antitumor activity 31, 32 and the rapid reconstitution of NK cells following ASCT 33 provide a compelling hypothesis for rituximab's efficacy in the post transplant setting. Nevertheless, it is difficult to draw firm conclusions regarding rituximab's impact on survival following ASCT failure, especially in comparison to other agents, and other reports on the use of rituximab for progressive disease after ASCT suggest variable benefit. 34, 35 Given the retrospective nature of our report and the small number of patients involved, we cannot conclude that the use of rituximab improves the survival of patients with aggressive B cell lymphoma after ASCT failure. However, these data provide the rationale to test rituximab's role in ASCT failure in formal prospective studies.
Anecdotal reports, including ours, suggest that second autologous transplants 6, 36 and conventional allogeneic transplantation after the failure of autologous transplantation are rarely curative, [36] [37] [38] [39] [40] with disease-and transplantrelated mortality being the primary causes of failure with second autologous and allogeneic transplants, respectively. However, the variability in the timing of second transplants and in the clinical characteristics of the patients precludes definitive conclusions. Nevertheless, the indolent course that characterizes relapses of HD and late relapses of aggressive NHL offers an opportunity to explore second transplants in these settings, especially using novel approaches such as radioimmunotherapy-based conditioning regimens 41 and nonmyeloablative allogeneic transplantation. In the setting of disease progression after ASCT, nonmyeloablative allogeneic transplantation appears to have lower rates of transplant-related mortality compared to conventional transplantation, with long-term diseasefree survival rates reported to be between 20 and 35%. [42] [43] [44] These encouraging results warrant prospective studies of this approach.
There are several limitations of this retrospective analysis that should be acknowledged. In some respects, the patients reported in this series may represent a population with a 'good prognosis' since they all had chemosensitive disease and since they were all treated on clinical trials. This may explain, in part, their better survival compared to what has been reported by Vose et al 6 and Shamash et al, 7 where a significant proportion of patients were resistant to secondline chemotherapy, a feature known to confer a poor prognosis. In addition, our population of patients may not be well matched with those studied in previous reports with respect to prognostic factors such as time to progression, sIPI and the HDPS, and therefore direct comparisons of results may not be appropriate. Lastly, a proportion of patients could not be evaluated for therapy after disease progression, limiting the power of our analyses. Given these limitations and the number of patients studied, our observations should not be interpreted as definitive 'results' but rather as hypotheses that may warrant further study.
Patients with progressive disease after ASCT have a poor outcome with no reliably effective curative therapy currently available. It will probably be difficult to alter the outcome of ASCT-refractory patients, that is, those with overt disease progression soon after transplant. However, the identification of patients in a minimal disease state, as some studies suggest is possible, [45] [46] [47] may allow the introduction of novel post transplant nonmyelosuppressive therapy, such as monoclonal antibodies and adoptive cellular therapy, that may eradicate residual disease and thereby prevent late relapses. Therefore, in addition to the development of novel agents and modalities to treat patients with overt disease progression after ASCT failure, efforts should be directed at assessing the utility and feasibility of detecting and treating ASCT failure early, in a minimal residual disease state.
